Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | MDM4 | O15151 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8603038 | 1.00 | ATM (0.58) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL11406714 | 1.00 | ATM (0.58) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL9301967 | 1.00 | ATM (0.58) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| Hydrochloric Acid SCHEMBL9492789 | 0.99 | ATM (0.56) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL8603938 | 0.93 | ATM (0.59) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL8603937 | 0.93 | ATM (0.59) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| Hydrochloric Acid SCHEMBL10412319 | 0.92 | ATM (0.58) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL8086148 | 0.92 | ALDH1A1 (0.55) | ATMKLK5ALDH1A1THRBCYP2C9 | |
| SCHEMBL237136 | 0.89 | ACE (0.57) | ATMKLK5 | |
| SCHEMBL22013341 | 0.89 | ATM (0.60) | ATMKLK5ALDH1A1THRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0510552-B2 | Preparation process of alpha-aspartyl-L-phenylalanine methyl ester | MITSUI TOATSU CHEMICALS (JP) | 2000-11-15 | — | — | EP | claimed |
| EP-0526854-B1 | Method for recovery of alpha-L-aspartyl-L-phenylalanine methyl ester, L-phenylalanine and l-aspartic acid | AJINOMOTO KK (JP) | 1997-05-02 | — | — | EP | claimed |
| EP-0556485-B1 | Method for purifying alpha-L-aspartyl-L-phenylalanine methyl ester | AJINOMOTO KK (JP) | 1995-11-15 | — | — | EP | claimed |
| US-5424477-A | Preparation process of α-aspartyl-L-phenylalanine methyl ester | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1995-06-13 | — | — | US | claimed |
| US-5304671-A | Solid-liquid separation of suspension; no desalting; precipitation of acid salt; neutralization; hydrolysis | AJINOMOTO CO., INC. (JP) | 1994-04-19 | — | — | US | claimed |
| EP-0556485-A1 | Method for purifying alpha-L-aspartyl-L-phenylalanine methyl ester | Ajinomoto Co., Inc. (JP) | 1993-08-25 | — | — | EP | claimed |
| US-5225587-A | Method of producing α-L-aspartyl-L-phenylalanine methyl ester hydrochloride | AJINOMOTO CO., INC. (JP) | 1993-07-06 | — | — | US | claimed |
| WO-1993010677-A1 | SPECIFIC EATABLE TASTE MODIFIERS | BIORESEARCH, INC. (US) | 1993-06-10 | — | — | WO | claimed |
| EP-0510552-A1 | Preparation process of alpha-aspartyl-L-phenylalanine methyl ester | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-10-28 | — | — | EP | claimed |
| JP-63150295-A | — | — | None | — | — | JP | disclosed |
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | SHENZHEN JINGTAI TECHNOLOGY CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| CN-118234705-A | Aspartic acid derivative and application thereof in treatment of liver fibrosis, nonalcoholic hepatitis and other metabolic diseases | 深圳利沃生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-109477116-B | Rebaudioside analogues | 百事可乐公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023083291-A1 | DERIVATIVE OF ASPARTIC ACID AND USE THEREOF IN TREATMENT OF METABOLIC DISEASES SUCH AS HEPATIC FIBROSIS AND NON-ALCOHOLIC HEPATITIS | 深圳利沃生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-0132856-A2 | Process for preparing alpha-L-aspartyl-L-phenylalanine methyl ester | DE-BI DERIVATI BIOLOGICI INTERNATIONAL S.p.A. (IT) | 1985-02-13 | — | — | EP | disclosed |
| EP-0127411-A2 | Method of preparing alpha-l-aspartyl-l-phenylalanine methyl ester and its hydrochloride | AJINOMOTO CO., INC. (JP) | 1984-12-05 | — | — | EP | disclosed |
| EP-0102529-A2 | Process for preparation of aspartylphenylalanine alkyl esters | Tosoh Corporation (JP) | 1984-03-14 | — | — | EP | disclosed |
| EP-0092933-A1 | Process for producing alpha-L-aspartyl-L-phenylalanine methyl ester or its hydrochloride | AJINOMOTO CO., INC. (JP) | 1983-11-02 | — | — | EP | disclosed |
| EP-0074095-A1 | Process for preparation of aspartylphenylalanine alkyl esters | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1983-03-16 | — | — | EP | disclosed |
| US-4017472-A | Process for isolation of aspartyl dipeptide esters | G. D. SEARLE & CO. (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025438-A1 | Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis | GOT1, GOT2, GLS2 | ATM 2208/4885KLK5 1770/4885ALDH1A1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.